2025 年 8 月 29 日 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： 註： J.P. Morgan Securities PLC 是與要約人有關連的第(5)類別聯繫人。 交易披露 交易披露 交易是為本身帳戶進行的。 J.P. Morgan Securities PLC 是最終由 JPMorgan Chase & Co.擁有的公司。 | 交易方 | 日期 | | | 有關證券的說 | 交易性質 | 買入／賣 | 涉及的股份 | 已支付／已收取 | 已支付或已 | 已支付或已 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 明 | | 出 | 總數 | 的總金額 | 收取的最高 | 收取的最低 | | | | | | | | | | | 價（H） | 價（L） | | J.P. Morgan | 2025 | 年 | 8 月 | 其他類別的證 | 因全屬客戶主動發出且由客戶需求帶動的買賣 | 買入 ...

集团高度重视产品研发，并计划持续增加研发开支。集团目前的产品组合包含丰富的微创手术设备、器 械和耗材，涵盖整个手术流程，从创建通路和建立腹腔气腹，到术中切割、解剖、凝固、闭合、视觉化 系统和伤口闭合，可提供完整的一站式微创手术解决方案。2025年上半年，集团的多项产品获得中国国 家药品监督管理局的批准，包括集团的4K3D萤光内窥镜摄像系统、4K3D萤光腹腔镜、硬性宫腔镜和一 次性膀胱镜。同时，集团的集成式超声与高频手术刀、微波消融仪以及一次性微波消融电极均已进入注 册审查阶段，预计将于2025年下半年获得批准。在集团的手术缝合线产品组合中，去年推出的可吸收免 打结缝合线满足重要临床需求。这款创新产品具有优越的生物相容性，适用于多种临床应用场景，并具 备多种规格可供选择，可满足不同的手术需求。此外，集团新推出的连发结扎夹和连发钛夹则透过全面 的结扎与闭合解决方案提高手术效率，目前集团正针对该等产品进行临床市场推广。 格隆汇8月28日丨康基医疗(09997.HK)发布公告，截至2025年6月30日止六个月，报告期内，公司实现人 民币4.97亿元的收入，相较2024年同期增长8.3%，母公司拥有人应占纯利达到人民币 ...

康基医疗(09997)发布截至2025年6月30日止6个月中期业绩，集团收入人民币4.97亿元，同比增长8.3%; 股东应占溢利2.66亿元，同比减少7%;每股盈利22.56分。 ...

[Financial Highlights](index=1&type=section&id=%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) Kangji Medical's H1 2025 unaudited results show **8.3%** revenue growth to **RMB496.6 million**, but **7.0%** profit decline to **RMB265.8 million** due to reduced other income and higher associate losses; no interim dividend is recommended Key Financial Data for H1 2025 (RMB thousands) | Metric | 2025 (Unaudited) | 2024 (Unaudited) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 496,555 | 458,413 | 8.3 | | Gross Profit | 392,361 | 363,123 | 8.1 | | Profit for the Period | 265,760 | 275,686 | (3.6) | | Profit Attributable to Owners of the Parent | 265,760 | 285,847 | (7.0) | | Non-IFRS Adjusted Net Profit Attributable to Owners of the Parent | 224,097 | 274,873 | (18.5) | | Basic Earnings Per Share (RMB) | 22.56 cents | 24.39 cents | (7.5) | | Diluted Earnings Per Share (RMB) | 22.56 cents | 24.39 cents | (7.5) | - Revenue growth was primarily attributable to increased sales of **disposable products**[2](index=2&type=chunk) - The decrease in profit attributable to owners of the parent was mainly due to a decrease in other income and gains and an increased share of loss from associate Weijing Medical[2](index=2&type=chunk) - The Board does not recommend the payment of any interim dividend for the six months ended June 30, 2025[3](index=3&type=chunk) [Interim Condensed Consolidated Financial Statements](index=2&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8) [Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=2&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E6%90%8D%E7%9B%8A%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) For the six months ended June 30, 2025, the company's revenue increased by **8.3%** to **RMB496.6 million**, and gross profit increased by **8.1%** to **RMB392.4 million**; however, profit for the period and profit attributable to owners of the parent both decreased due to lower other income and gains, increased loss from an associate, and higher income tax expense Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (RMB thousands) | Metric | 2025 (Unaudited) | 2024 (Unaudited) | | :--- | :--- | :--- | | Revenue | 496,555 | 458,413 | | Cost of Sales | (104,194) | (95,290) | | Gross Profit | 392,361 | 363,123 | | Other Income and Gains | 81,497 | 115,403 | | Selling and Distribution Expenses | (37,898) | (39,062) | | Administrative Expenses | (37,658) | (50,854) | | Research and Development Costs | (33,874) | (43,354) | | Share of Loss of an Associate | (19,542) | (5,868) | | Finance Costs | (46) | (614) | | Profit Before Tax | 324,876 | 327,733 | | Income Tax Expense | (59,116) | (52,047) | | Profit for the Period | 265,760 | 275,686 | | Profit Attributable to Owners of the Parent | 265,760 | 285,847 | | Total Comprehensive Income for the Period | 263,320 | 277,540 | - Other income and gains decreased year-on-year from **RMB115,403 thousand** in 2024 to **RMB81,497 thousand** in 2025[4](index=4&type=chunk) - Share of loss of an associate significantly increased from **RMB5,868 thousand** in 2024 to **RMB19,542 thousand** in 2025[4](index=4&type=chunk) [Interim Condensed Consolidated Statement of Financial Position](index=4&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E8%B2%A1%E5%8B%99%E7%8B%80%E6%B3%81%E8%A1%A8) As of June 30, 2025, the company's total assets slightly decreased, with total non-current assets decreasing and total current assets increasing; cash and cash equivalents significantly grew, but investments in an associate decreased, while total current liabilities substantially increased, mainly due to higher other payables and accruals Interim Condensed Consolidated Statement of Financial Position (RMB thousands) | Metric | June 30, 2025 (Unaudited) | December 31, 2024 (Audited) | | :--- | :--- | :--- | | Total Non-Current Assets | 777,727 | 854,645 | | Total Current Assets | 2,278,162 | 2,063,645 | | Total Assets Less Current Liabilities | 2,612,492 | 2,657,686 | | Total Current Liabilities | 443,397 | 260,604 | | Total Non-Current Liabilities | 18,108 | 28,791 | | Net Assets | 2,594,384 | 2,628,895 | | Cash and Cash Equivalents | 1,707,184 | 1,126,799 | | Inventories | 128,697 | 108,219 | | Trade Receivables | 278,478 | 271,949 | | Investments in an Associate | 345,331 | 377,797 | | Other Payables and Accruals | 359,953 | 150,320 | - Cash and cash equivalents increased from **RMB1,126,799 thousand** as of December 31, 2024, to **RMB1,707,184 thousand** as of June 30, 2025[6](index=6&type=chunk) - Total current liabilities significantly increased from **RMB260,604 thousand** as of December 31, 2024, to **RMB443,397 thousand** as of June 30, 2025, primarily due to an increase in other payables and accruals[7](index=7&type=chunk) [Interim Condensed Consolidated Statement of Cash Flows](index=6&type=section&id=%E4%B8%AD%E6%9C%9F%E7%B0%A1%E6%98%8E%E7%B6%9C%E5%90%88%E7%8F%BE%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For the six months ended June 30, 2025, net cash generated from operating activities was **RMB199.2 million**, a year-on-year decrease; net cash from investing activities shifted from a net inflow to a net outflow, mainly due to increased fixed deposits and purchases of financial assets; cash outflow from financing activities decreased, and the net increase in cash and cash equivalents was significantly lower than the prior year Interim Condensed Consolidated Statement of Cash Flows (RMB thousands) | Metric | 2025 (Unaudited) | 2024 (Unaudited) | | :--- | :--- | :--- | | Net Cash Generated from Operating Activities | 199,227 | 221,722 | | Net Cash (Used in)/Generated from Investing Activities | (66,343) | 1,213,364 | | Net Cash Used in Financing Activities | (4,658) | (35,692) | | Net Increase in Cash and Cash Equivalents | 128,226 | 1,399,394 | | Cash and Cash Equivalents at End of Period | 1,535,846 | 2,915,728 | - Net cash from investing activities shifted from a net inflow of **RMB1,213,364 thousand** in the same period of 2024 to a net outflow of **RMB66,343 thousand** in the same period of 2025, mainly impacted by an increase in fixed deposits and purchases of financial assets measured at fair value[9](index=9&type=chunk) - Cash and cash equivalents at the end of

2025 年 8 月 28 日 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的 | 交易性質 | 買入／賣 | 涉及的股份 | 已支付／已收取的 | 已支付或已 | 已支付或已 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 說明 | | 出 | 總數 | 總金額 | 收取的最高 | 收取的最低 | | | | | | | | | | | 價（H） | 價（L） | | J.P. Morgan | 2025 | 年 | 8 月 | 其他類別的 | 因全屬客戶主動發出且由客戶需求帶動的買賣 | 買入 | 45,000 | $390,683.2100 | $8.7000 | $8.6500 | | Securities | 27 | 日 | | 證券 (例如: | 盤所產生的 Delta 1 產品的對沖活動 | | | | | | | PLC | | | | 股 ...

交易披露 2025 年 8 月 28 日 透過協議安排進行私有化 就康基醫療控股有限公司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | 有關證券的說 | 產品說明 | 交易性質 | 與衍生工具有 | 到期日或清結 | 參考價 | 已支付／已收取的 | 交易後數額（包 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 明 | | | 關的參照證券 | 日 | | 總金額 | 括與其訂有協議 | | | | | | | 數目 | | | | 或達成諒解的任 | | | | | | | | | | | 何人士的證券） | | J.P. Morgan | 2025年8月27 | 衍生工具 | 其他類別產品 | 發行衍生工具 | 45,000 | 2026年2月10 | $8.6828 | $390,726.0000 | 9,364,503 | | Securities | 日 | | | | | 日 | | | | | PLC | | 衍生工具 | 其 ...

Key Points - The top three companies with net inflows of southbound funds are Alibaba-W (09988) with 581 million, Kangfang Biotech (09926) with 541 million, and Hong Kong Stock Exchange (00388) with 434 million [1] - The top three companies with net outflows of southbound funds are Yingfu Fund (02800) with -2.396 billion, Xiaomi Group-W (01810) with -1.524 billion, and SMIC (00981) with -845 million [1] - In terms of net inflow ratios, the top three companies are Quan Feng Holdings (02285) at 51.60%, Sen Song International (02155) at 49.91%, and GX China (03040) at 43.94% [1] - The top three companies with the highest net outflow ratios are Yihai International (01579) at -51.63%, Zhou Hei Ya (01458) at -49.54%, and Kangji Medical (09997) at -46.09% [1] Net Inflow Rankings - Alibaba-W (09988) had a net inflow of 581 million, representing a 2.88% increase in closing price to 124.500 [2] - Kangfang Biotech (09926) saw a net inflow of 541 million, with a closing price of 169.500, down 4.18% [2] - Hong Kong Stock Exchange (00388) experienced a net inflow of 434 million, closing at 462.800, up 3.30% [2] - Kuaishou-W (01024) had a net inflow of 428 million, closing at 78.750, up 5.14% [2] - Horizon Robotics-W (09660) recorded a net inflow of 401 million, closing at 7.760, up 1.31% [2] Net Outflow Rankings - Yingfu Fund (02800) had the largest net outflow of -2.396 billion, with a closing price of 26.360, up 2.01% [2] - Xiaomi Group-W (01810) experienced a net outflow of -1.524 billion, closing at 53.500, up 1.81% [2] - SMIC (00981) saw a net outflow of -845 million, with a closing price of 57.800, up 1.58% [2] - CNOOC (00883) had a net outflow of -708 million, closing at 18.830, up 0.53% [2] - Pop Mart (09992) recorded a net outflow of -418 million, closing at 326.600, up 1.94% [2] Net Inflow Ratio Rankings - Quan Feng Holdings (02285) had a net inflow ratio of 51.60%, with a net inflow of 24.33 million, closing at 24.300, up 5.29% [3] - Sen Song International (02155) recorded a net inflow ratio of 49.91%, with a net inflow of 54.68 million, closing at 10.900, up 1.68% [3] - GX China (03040) had a net inflow ratio of 43.94%, with a net inflow of 1.29 million, closing at 37.820, up 2.55% [3] Net Outflow Ratio Rankings - Yihai International (01579) had a net outflow ratio of -51.63%, with a net outflow of -69.47 million, closing at 14.780, up 4.23% [3] - Zhou Hei Ya (01458) recorded a net outflow ratio of -49.54%, with a net outflow of -20.12 million, closing at 2.570, up 2.80% [3] - Kangji Medical (09997) had a net outflow ratio of -46.09%, with a net outflow of -30.83 million, closing at 8.680, up 0.35% [3]

執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說 | 交易性質 | 買入／賣 | 涉及的股份 | 已支付／已收取 | 已支付或已 | 已支付或已 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 明 | | 出 | 總數 | 的總金額 | 收取的最高 | 收取的最低 | | | | | | | | | | | 價（H） | 價（L） | | J.P. Morgan | 2025 | 年 | 8 月 | 其他類別的證 | 因全屬客戶主動發出且由客戶需求帶動的買賣 | 買入 | 3,500 | $30,346.6000 | $8.6800 | $8.6500 | | Securities | 25 | 日 | | 券 (例如: 股 | 盤所產生的 Delta 1 產品的對沖活動 | | | | | | | PLC | | | | 權互換) | | | | | | | | | | | | 指數相關產品 | 就以包括相關證券在內的 ...

2025 年 8 月 26 日 透過協議安排進行私有化 就康基医疗控股有限公 司的股份的交易披露 執行人員接獲依據香港《公司收購及合併守則》規則 22 作出以下的證券交易的披露： | 交易方 | 日期 | | | 有關證券的說 | 產品說明 | 交易性質 | 與衍生工具有 | | 到期日或清結 | | 參考價 | 已支付／已收 | 交易後數額（包 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 明 | | | 關的參照證券 | | 日 | | | 取的總金額 | 括與其訂有協議 | | | | | | | | | 數目 | | | | | | 或達成諒解的任 | | | | | | | | | | | | | | | 何人士的證券） | | J.P. Morgan | 2025 | 年 8 | 月 25 | 衍生工具 | 其他類別產品 | 清結衍生工具合約 | | 4,000 | 2026 年 月 | 8 19 | | $8.6702 $34,680.8000 | ...

每经AI快讯，8月25日，康基医疗(09997.HK)公告，J.P.MorganSecuritiesPLC于2025年8月22日买入公司 股份22.95万股，每股交易价格为8.61—8.67港元，总金额为198.53万港元。J.P.MorganSecuritiesPLC是与 要约人有关联的第(5)类联系人，此次交易是为自身账户进行的，该公司最终由JPMorganChase&Co.拥 有。 ...